Lilly Sees Payoff In China By Boning Up On Tax And Patent Law
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - Adept management of tax, patent and government relations issues particular to China can help Western pharmaceutical companies reap the benefits of working in the vast, developing market while avoiding pitfalls